How Exazym Improves ELISA Sensitivity
Every researcher faces practical constraints: limited budgets, tight timelines, equipment you’ve already invested in, and antibody pairs you’ve spent months validating. These aren’t obstacles to ignore—they’re the reality of working in science. That’s why Exazym® was built to improve ELISA sensitivity within existing workflows, not replace them.
When new technologies promise breakthroughs, the first question is rarely how powerful it is. It’s usually simpler—and more practical: Will this work in my lab, or will it create more problems than it solves?
Here are five common challenges researchers raise—and how Exazym has been used to address them.
1. Biomarker Detection Hits a Ceiling
The Problem:
Standard ELISA methods often reach limits of detection around 10-12 pg/mL, while many biomarkers exist at much lower concentrations. Improving sensitivity can feel like starting over.
How Exazym Helps:
Depending on the biomarker and assay conditions, Exazym has demonstrated 50–180× sensitivity improvements. In cardiac troponin I assays, detection down to 0.07 pg/mL has been achieved—without abandoning existing assay formats.
2. Background Noise Undermines Results
The Problem:
Some amplification techniques increase sensitivity at the expense of signal-to-noise, complicating interpretation and reducing confidence in the data.
How Exazym Helps:
Exazym’s BOLD signal amplification is designed to amplify true signal while maintaining low background. The Gyros team’s recent work demonstrates this principle—they achieved 10-fold improvements in signal-to-background for neurofilament light chain (NfL), showing that Exazym amplifies the true signal while keeping noise low. With appropriate antibody selection and optimization, researchers can achieve higher sensitivity without the noise that often accompanies amplification.
3. New Equipment Isn’t an Option
The Problem:
Ultra-sensitive platforms frequently require proprietary instruments with high capital costs.
How Exazym Helps:
Exazym integrates with standard ELISA readers already in most labs. No specialized instrumentation is required—making Exazym ELISA sensitivity gains a reagent-level decision rather than a capital investment.
4. Antibodies Are Already Validated
The Problem:
Switching antibody pairs means re-optimizing assays and repeating months of work.
How Exazym Helps:
Exazym is compatible with existing antibody pairs, allowing researchers to build on validated assays rather than replace them.
5. Workflow Changes Add Friction
The Problem:
Even modest protocol changes can slow teams down.
How Exazym Helps:
In typical ELISA workflows, Exazym adds approximately 10–60 minutes—enough to achieve significant sensitivity gains without disrupting your team’s established processes or requiring retraining.
Moving Forward
These aren’t theoretical problems. They’re challenges researchers encounter across drug discovery, biomarker development, neurology, and diagnostics.
If one of these challenges resonates with your work, let’s talk—we’d like to understand your specific assay and discuss whether Exazym makes sense for your lab.
Because effective tools adapt to the realities of the lab—not the other way around.